This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yajima, T. Articles by Knowlton, K. U. Search for Related Content PubMed PubMed Citation Articles by Yajima, T. Articles by Knowlton, K. U. Related Collections Other heart failure Heart failure - basic studies Myocardial cardiomyopathy disease

(Circulation. 2009;119:2615-2624.)
© 2009 American Heart Association, Inc.

Basic Science for Clinicians

Viral Myocarditis

From the Perspective of the Virus

Toshitaka Yajima, MD, PhD; Kirk U. Knowlton, MD

From the Division of Cardiology, Department of Medicine, University of California, San Diego, La Jolla.

Correspondence to Kirk U. Knowlton, MD, Department of Medicine, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA 92093–0613K. E-mail kknowlton@ucsd.edu

Key Words: cardiomyopathy • heart failure • immune system • myocarditis • viruses

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Viral myocarditis has been recognized as a cause of congestive heart failure for >50 years, but it is still a challenging disease to diagnose and treat.^1,2 The history and clinical features are often nonspecific, and practical serological markers are not available during the acute phase of the disease. Even after proper diagnosis, no clinically proven treatment exists to inhibit the development of subsequent dilated cardiomyopathy (DCM) and, in some cases, death. Accordingly, to facilitate future scientific work into this difficult clinical entity, this review proposes a clinical paradigm that focuses on the phases of viral infection and the molecular insights that are important for these phases of the infectious process with a focus on interactions between the virus and the cardiac myocyte.

Myocarditis is defined as inflammation of the heart muscle. The gold standard for diagnosis has been the Dallas criteria based on histopathology from an endomyocardial biopsy.³ It is now recognized that the Dallas criteria are not sensitive for myocarditis because they do not consider the presence of viral genome in the heart.⁴ Furthermore, an invasive procedure is required to obtain a sample of the myocardium.

Many viruses have been implicated as causes of myocarditis. These most commonly include adenoviruses and enteroviruses such as the coxsackieviruses. Recently, parvovirus B19 has been associated with a significant percentage of patients diagnosed with myocarditis and DCM.⁵ However, a growing body of data indicates that parvovirus is present in a large percentage of patients who do not have myocarditis.^6–8 Of the viruses that . . . [Full Text of this Article]

This article has been cited by other articles:

				L. Venteo, T. Bourlet, F. Renois, F. Douche-Aourik, J.-F. Mosnier, G. Lorain De la Grand Maison, M. Pluot, B. Pozzetto, and L. Andreoletti Enterovirus-related activation of the cardiomyocyte mitochondrial apoptotic pathway in patients with acute myocarditis Eur. Heart J., November 19, 2009; (2009) ehp489v1. [Abstract] [Full Text] [PDF]